Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
Anti-Pd-1, Sd-101
Locally Advanced Pancreatic Adenocarcinoma
Phase I
Active Not Recruiting
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
Oct 19, 2022
―
Pembrolizumab, Nivolumab, Ipilimumab, Sd-101
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Phase I/II
Terminated
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Jan 21, 2022
―
Nivolumab, Ipilimumab, Sd-101, Nivolumab And Relatlimab
Metastatic Uveal Melanoma In The Liver
Phase I
Terminated
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Jun 02, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does TriSalus Life Sciences (TLSI) have in its pipeline
TLSI is currently developing the following drugs: Anti-Pd-1, Sd-101, Pembrolizumab, Nivolumab, Ipilimumab, Sd-101, Nivolumab, Ipilimumab, Sd-101, Nivolumab And Relatlimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.